27 January 2016

Merck increases its contribution to the Pediatric Praziquantel Consortium

After completion of the Phase I bioavailability trials and of the taste study, the Pediatric Praziquantel Program is progressing to the Phase II development stage.

To support Phase II, Merck KGaA (Darmstadt, Germany) is broadening its contribution to entail, in addition to the leadership, expertise and resources from different areas of the biopharmaceutical sector, the work performed by Merck Performance Materials. Specifically, Performance Materials is responsible for the development of L-PZQ Active Pharmaceutical Ingredient (API), a key component of the L-PZQ orally-disintegrating tablet development project.

The manufacturing process for the L-PZQ API has already been developed, with special emphasis on manufacturability and economy at larger scales. The additional contribution by Merck KGaA (Darmstadt, Germany) has been significant and will be essential for the progression of the program through a number of critical manufacturing activities and the technical expertise and experience of the Performance Materials team.